Key Takeaways
- Generic drug companies may worry about transitioning metered dose inhaler products to new lower global warming potential propellants, but the FDA stressed they should continue product development.
The US Food and Drug Administration wants generic drug companies to continue working on metered dose inhaler (MDI) products amid...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?